Monday 24 September 2018

Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market

24 September 2018: According to a report by Grand View Research, Inc., the worldwide acute lymphocytic/lymphoblastic leukemia therapeutics market is likely to accomplish USD 3.4 billion through 2025. Acute lymphocytic/lymphoblastic leukemia therapeutics are used to treat different types of acute leukemia such as Philadelphia chromosome, precursor B-cell ALL, and T-cell ALL. Various therapies include chemotherapy, targeted therapy, radiation therapy, and stem cell transplantation.

On June 3, 2017, QIAGEN and Bristol-Myers Squibb Company signed contract to discover the use of next generation sequencing (NGS) technique for developing gene expression profiles (GEPs) as predictive tools for use with immuno-oncology (I-O) therapies in cancer treatment, which is develop by Bristol-Myers Squibb Company. The companies are also planning to develop diagnostic products by making use of GEPs and will also supposed to use NGS technology with other I-O therapies developed by Bristol-Myers Squibb I-O. Since I-O therapies help to treat cancer by utilizing drugs to target the body’s immune system for fighting cancer.




On August 17, 2017, Pfizer Inc. announced about approval of its product called BESPONSA (inotuzumab ozogamicin) by the U.S. Food and Drug Administration (FDA). The product can be used as a monotherapy to treat adults suffering from refractory CD22-positive B-cell precursor acute ALL.

On June 30, 2017, Pfizer Inc. gets an approval from European Commission for its product called BESPONSA.

On November 1, 2017, Pfizer Inc. and Cellectis announced the initial results of two phase 1 trials for UCART19 CAR T-cell product. This data presented during American Society of Hematology (ASH) annual summit and exposition, which was held in Atlanta on December 9 to 12, 2017. The CALM study, an open label, dose expansion study intended to estimate tolerability, antileukemic activity, and safety of UCART19 in patients with reverted or refractory CD19-positive B-cell acute lymphoblastic leukemia. 

Rising prevalence of lymphocytic leukemia (ALL), growing public and private initiatives for ALL and awaiting innovative therapies can propel acute lymphocytic/lymphoblastic leukemia therapeutics market over the forecast period (2014 to 2025).

Key players operating in the market include Spectrum Pharmaceuticals, Inc.; Genzyme Corporation; Erytech Pharma; Sigma-Tau s.p.a., and Pfizer, Inc.

Read more @ 



No comments:

Rising Mining and Construction Activities Boost Utility Trucks Demand

26 November 2020: Utility vehicles are motorized vehicles that carry out a particular task more effectively than a passenger vehicle. Utili...